EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 399 filers reported holding EXELIXIS INC in Q3 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,611,099 | -4.6% | 71,700 | +0.8% | 0.00% | 0.0% |
Q1 2024 | $1,688,437 | -14.7% | 71,152 | -13.7% | 0.00% | -50.0% |
Q4 2023 | $1,978,911 | +16.7% | 82,489 | +6.3% | 0.00% | +100.0% |
Q3 2023 | $1,695,036 | +2.8% | 77,576 | -10.1% | 0.00% | 0.0% |
Q2 2023 | $1,649,423 | -12.2% | 86,312 | -10.8% | 0.00% | -33.3% |
Q1 2023 | $1,877,550 | +55.7% | 96,731 | +28.7% | 0.00% | +50.0% |
Q4 2022 | $1,205,647 | +1.6% | 75,165 | -0.7% | 0.00% | 0.0% |
Q3 2022 | $1,187,000 | -24.2% | 75,683 | +0.6% | 0.00% | -33.3% |
Q2 2022 | $1,566,000 | -9.3% | 75,228 | -1.2% | 0.00% | 0.0% |
Q1 2022 | $1,727,000 | +21.4% | 76,179 | -2.1% | 0.00% | +50.0% |
Q4 2021 | $1,422,000 | -18.9% | 77,777 | -6.2% | 0.00% | -33.3% |
Q3 2021 | $1,753,000 | +13.5% | 82,904 | -2.2% | 0.00% | 0.0% |
Q2 2021 | $1,545,000 | -38.9% | 84,776 | -24.3% | 0.00% | -40.0% |
Q1 2021 | $2,530,000 | +5.8% | 112,004 | -6.0% | 0.01% | 0.0% |
Q4 2020 | $2,392,000 | +21.1% | 119,159 | +47.5% | 0.01% | 0.0% |
Q3 2020 | $1,975,000 | +1.3% | 80,783 | -1.7% | 0.01% | -16.7% |
Q2 2020 | $1,950,000 | +57.5% | 82,141 | +14.2% | 0.01% | +50.0% |
Q1 2020 | $1,238,000 | -1.5% | 71,901 | +0.8% | 0.00% | 0.0% |
Q4 2019 | $1,257,000 | -68.0% | 71,342 | -67.9% | 0.00% | -69.2% |
Q3 2019 | $3,934,000 | -21.0% | 222,436 | -4.6% | 0.01% | -23.5% |
Q2 2019 | $4,981,000 | +6.3% | 233,106 | +18.4% | 0.02% | 0.0% |
Q1 2019 | $4,685,000 | -4.8% | 196,842 | -21.3% | 0.02% | -15.0% |
Q4 2018 | $4,919,000 | -6.3% | 250,101 | -15.5% | 0.02% | +5.3% |
Q3 2018 | $5,247,000 | +144.2% | 296,098 | +196.5% | 0.02% | +137.5% |
Q2 2018 | $2,149,000 | -15.1% | 99,881 | -12.6% | 0.01% | -20.0% |
Q1 2018 | $2,532,000 | -23.1% | 114,319 | +5.6% | 0.01% | -28.6% |
Q4 2017 | $3,292,000 | +47.0% | 108,297 | +17.2% | 0.01% | +40.0% |
Q3 2017 | $2,239,000 | -1.8% | 92,387 | -0.2% | 0.01% | -16.7% |
Q2 2017 | $2,279,000 | +107.0% | 92,538 | +82.1% | 0.01% | +100.0% |
Q1 2017 | $1,101,000 | -5.3% | 50,808 | -34.8% | 0.01% | -14.3% |
Q4 2016 | $1,163,000 | +7.2% | 77,986 | -8.0% | 0.01% | 0.0% |
Q3 2016 | $1,085,000 | +162.7% | 84,813 | +60.2% | 0.01% | +133.3% |
Q2 2016 | $413,000 | +118.5% | 52,930 | +12.3% | 0.00% | +200.0% |
Q1 2016 | $189,000 | -57.1% | 47,146 | -39.7% | 0.00% | -75.0% |
Q4 2015 | $441,000 | +31.2% | 78,141 | +30.6% | 0.00% | +33.3% |
Q3 2015 | $336,000 | +80.6% | 59,841 | +21.0% | 0.00% | +50.0% |
Q2 2015 | $186,000 | +66.1% | 49,457 | +13.1% | 0.00% | +100.0% |
Q1 2015 | $112,000 | +75.0% | 43,733 | -0.9% | 0.00% | 0.0% |
Q4 2014 | $64,000 | -32.6% | 44,133 | -28.8% | 0.00% | 0.0% |
Q3 2014 | $95,000 | -31.7% | 61,957 | +50.9% | 0.00% | -50.0% |
Q2 2014 | $139,000 | -5.4% | 41,057 | -1.0% | 0.00% | 0.0% |
Q1 2014 | $147,000 | +539.1% | 41,457 | +989.0% | 0.00% | – |
Q4 2013 | $23,000 | -39.5% | 3,807 | -41.4% | 0.00% | -100.0% |
Q3 2013 | $38,000 | +111.1% | 6,500 | +62.5% | 0.00% | – |
Q2 2013 | $18,000 | – | 4,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |